POLARx™
Cryoablation System
Explore
![Clinical evidence chart](https://www.bostonscientific.com/en-US/products/catheters--ablation/polarx/clinical-evidence/_jcr_content/maincontent-par/image_657968270.img.polarx-clinical-evidence-chart-3.jpg)
*Only ablations with duration >60S included in ablation counts
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-82-percent.jpg)
Freedom from atrial arrhythmias
at follow-up (12 months) after using POLARx FIT
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-0-adverse-events.png)
Major adverse events
including esophageal fistulas, persistent phrenic nerve palsy and PV stenosis
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-97-percent.jpg)
High-grade occlusion rate
resulting in either Grade 3 or Grade 4 occlusion level
![Frozen AF clinical trial](https://www.bostonscientific.com/en-US/products/catheters--ablation/polarx/clinical-evidence/_jcr_content/maincontent-par/image_398210252.img.polarx-FROzEN-AF-clinical-trial-bar.png)
![download the clinical compendium](https://www.bostonscientific.com/en-US/products/catheters--ablation/polarx/clinical-evidence/_jcr_content/maincontent-par/image_398210252_copy.img.polarx-clinical-compendium-download-bar.png)
POLAR ICE multicenter study
![POLAR ICE multicenter study](https://www.bostonscientific.com/en-US/products/catheters--ablation/polarx/clinical-evidence/_jcr_content/maincontent-par/image_398210252_copy_2098094498.img.polarx-POLAR-ICE-multicenter-study-bar.png)
ANTARCTICA observational study
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-99.7-percent.png)
Acute PV isolation
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-71.9-percent.png)
Real-time PVI visualization
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-86.1-percent.png)
Freedom from recurrence
at 226 ± 115 days
![ANTARTICA observational study](https://www.bostonscientific.com/en-US/products/catheters--ablation/polarx/clinical-evidence/_jcr_content/maincontent-par/image_398210252_copy_1398944968.img.polarx-ANTARCTICA-observational-study-bar.png)
Performance vs. existing cyroablation systems
Prospective ICE AGE 1 Study
![Polarx vs. Arctic Front - Prospective ICE AGE 1 Study](https://www.bostonscientific.com/en-US/products/catheters--ablation/polarx/clinical-evidence/_jcr_content/maincontent-par/image_copy.img.polarx-vs-arctic-front-advance-pro.jpg)
![Heeger et al comparison study](https://www.bostonscientific.com/en-US/products/catheters--ablation/polarx/clinical-evidence/_jcr_content/maincontent-par/image_398210252_copy_2061663784.img.polarx-heeger-finding-clinical-trial-bar.png)
U.K. Comparative Study
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-UK-study-image1.png)
Reported phrenic nerve palsy6
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-UK-study-image2.png)
Complication rate6
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-UK-study-image3.png)
Procedure time6
![Review data from the study United Kingdom POLARx versus AFA experience](https://www.bostonscientific.com/en-US/products/catheters--ablation/polarx/clinical-evidence/_jcr_content/maincontent-par/image_398210252_copy_397316553.img.polarx-vs-AFA-clinical-trial-bar.png)
Propensity Score-Matched Comparison
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-16-percent.png)
Faster procedure time
vs. Arctic Front Advance
(61 min. vs. 73 min.)
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-37-percent.png)
Faster to -40˚C
vs. Arctic Front Advance
(30 sec. vs. 48 sec.)
![](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-14-percent.png)
Greater real-time isolation rate
vs. Arctic Front Advance
(84% vs. 70%)
Procedural characteristics
![Polarx vs. Arctic Front - Procedural characteristics](https://www.bostonscientific.com/en-US/products/catheters--ablation/polarx/clinical-evidence/_jcr_content/maincontent-par/image.img.EP-1372110-AA%20POLARx_Infographics_Mojica_Final.png.png)
![Mojica comparison study](https://www.bostonscientific.com/en-US/products/catheters--ablation/polarx/clinical-evidence/_jcr_content/maincontent-par/image_398210252_copy_1060759703.img.polarx-Head-to-head-comparison-bar.png)
Studies comparing POLARx™ and other cryoablation systems
![Doctor looking at a laptop screen Doctor looking at a laptop screen](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-RecentStudies.png)
![Explore on Educare Explore on Educare](/content/dam/bostonscientific/ep/Electrophysiology%20Portfolio/polarx/polarx-product-page/polarx-educare-hero-2.jpg)
Advance your understanding
Continue exploring POLARx technology on EDUCARE, Boston Scientific’s online medical education platform.
References:
1. Ellenbogen KA, Mittal S, Varma N, et al. One-year outcomes of pulmonary vein isolation with a novel cryoballoon: Primary results of the FROZEN AF trial. J Cardiovasc Electrophysiol. 2024 March 6. doi.org/10.1111/jce.16220
2. Luik A, Anic A, Asmundis C, et al. Long-term success rates of a stable, low pressure cryoballoon for the treatment of paroxysmal atrial fibrillation: Results of the prospective, international, multicenter POLAR-ICE Study. Presented at: 2023 ESC Congress, Aug. 25-28, 2023; Amsterdam, Netherlands.
3. Martin CA, Tilz RRR, Anic A, et al. Acute procedural efficacy and safety of a novel cryoballoon for the treatment of paroxysmal atrial fibrillation: Results from the POLAR ICE study. J Cardiovasc Electrophysiol. 2023 Apr;34(4):833-840. doi: 10.1111/jce.15861. Epub 2023 Feb 23. PMID: 36786515.
4. Heeger CH, Pott A, Sohns C, et al. Novel cryoballoon ablation system for pulmonary vein isolation: multicenter assessment of efficacy and safety-ANTARCTICA study. Europace. 2022 Dec 9;24(12):1917-25
5. Heeger C-H, Popescu SS, Inderhees T. et al. Novel or established cryoballoon ablation system for pulmonary vein isolation: the prospective ICE-AGE-1 study. Europace. 2023 Aug 2;25(9):euad248. doi: 10.1093/europace/euad248.
6. Honarbakhsh S, Martin CA, Mesquita J, et al. AF cryoablation is an effective day case treatment: The United Kingdom PolarX versus AFA experience. EP Europace. Sept 21, 2023. euad286. doi.org/10.1093/europace/euad286
7. Mojica J, Lipartiti F, Al Housari M, et al. Procedural safety and efficacy for pulmonary vein isolation with the novel POLARx™ Cryoablation System: A propensity score matched comparison with the Arctic Front™ Cryoballoon in the setting of paroxysmal atrial fibrillation. J Atr Fibrillation. 2021 Jun 30;14(1):20200455.
† Updated analysis with corrected data.